These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 9831269

  • 1. Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.
    Newton M, Burnham WR, Kamm MA.
    Eur J Gastroenterol Hepatol; 1998 Sep; 10(9):753-8. PubMed ID: 9831269
    [Abstract] [Full Text] [Related]

  • 2. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole.
    Mee AS, Rowley JL.
    Aliment Pharmacol Ther; 1996 Oct; 10(5):757-63. PubMed ID: 8899084
    [Abstract] [Full Text] [Related]

  • 3. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
    Jaspersen D, Diehl KL, Schoeppner H, Geyer P, Martens E.
    Aliment Pharmacol Ther; 1998 Jan; 12(1):49-52. PubMed ID: 9692700
    [Abstract] [Full Text] [Related]

  • 4. Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison.
    Frazzoni M, De Micheli E, Grisendi A, Savarino V.
    Aliment Pharmacol Ther; 2002 Jan; 16(1):35-9. PubMed ID: 11856076
    [Abstract] [Full Text] [Related]

  • 5. Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison.
    Frazzoni M, Grisendi A, Lanzani A, Melotti G, De Micheli E.
    Dig Liver Dis; 2002 Feb; 34(2):99-104. PubMed ID: 11926567
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
    Janczewska I, Sagar M, Sjöstedt S, Hammarlund B, Iwarzon M, Seensalu R.
    Scand J Gastroenterol; 1998 Dec; 33(12):1239-43. PubMed ID: 9930385
    [Abstract] [Full Text] [Related]

  • 7. Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease.
    Wong WM, Lai KC, Hui WM, Lam KF, Huang JQ, Hu WH, Wong NY, Lam CL, Xia HH, Chan AO, Lam SK, Wong BC.
    Aliment Pharmacol Ther; 2004 Feb 15; 19(4):455-62. PubMed ID: 14871286
    [Abstract] [Full Text] [Related]

  • 8. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
    Bautista J, Fullerton H, Briseno M, Cui H, Fass R.
    Aliment Pharmacol Ther; 2004 May 15; 19(10):1123-30. PubMed ID: 15142202
    [Abstract] [Full Text] [Related]

  • 9. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood.
    Franco MT, Salvia G, Terrin G, Spadaro R, De Rosa I, Iula VD, Cucchiara S.
    Dig Liver Dis; 2000 Nov 15; 32(8):660-6. PubMed ID: 11142573
    [Abstract] [Full Text] [Related]

  • 10. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K, Lind T, Wilder-Smith C.
    Eur J Clin Pharmacol; 2004 Oct 15; 60(8):531-9. PubMed ID: 15349707
    [Abstract] [Full Text] [Related]

  • 11. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ, Dunn CJ, Mallarkey G, Sharpe M.
    Drugs; 2002 Oct 15; 62(7):1091-118. PubMed ID: 11985491
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole.
    Hatlebakk JG, Berstad A.
    Aliment Pharmacol Ther; 1997 Dec 15; 11(6):1093-9. PubMed ID: 9663835
    [Abstract] [Full Text] [Related]

  • 18. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
    Richter JE, Campbell DR, Kahrilas PJ, Huang B, Fludas C.
    Arch Intern Med; 2000 Jun 26; 160(12):1803-9. PubMed ID: 10871974
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P, Bianchi Porro G, Italian Rabeprazole Study Group.
    Dig Liver Dis; 2005 Oct 26; 37(10):741-50. PubMed ID: 16024305
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.